Pharma / Biotech

Management of Acute Coronary Syndrome Using Small-Molecule Glycoprotein IIb/IIIa Inhibitors: The Contemporary Role of Aggrastat (tirofiban hydrochloride) Injection for High-Risk Patients



This monograph discusses the current role of small-molecule GP IIb/IIa inhibitors in the management of patients at high risk for thrombotic events and describes the benefits of using Aggrastat (tirofiban hydrochloride) injection in customizing infusions for these patients.

Source link

Related posts

New Data Show 1-Hour Sepsis Bundle Works

Newsemia

pharmacokinetics; +159 new citations

Newsemia

ADENOSINE INJECTION, 6MG/2ML (3MG/ML) VIAL Injection, Solution [HF Acquisition Co. LLC, DBA Health First]

Newsemia

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy

COVID-19

COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World